BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, March 7, 2026
See today's BioWorld Asia
Home
» Certa Therapeutics’ FT-011 delivers breakthrough results in inflammatory, fibrotic diseases
To read the full story,
subscribe
or
sign in
.
American Society of Nephrology
Certa Therapeutics’ FT-011 delivers breakthrough results in inflammatory, fibrotic diseases
Nov. 8, 2022
By
Tamra Sami
New research presented by the University of Michigan revealed groundbreaking results for Certa Therapeutics Pty Ltd.’s lead candidate, FT-011, for serious inflammatory and fibrotic diseases.
BioWorld Asia
Clinical
Genitourinary/sexual function
Inflammatory